Total Payments
$16,143
2024 Payments
$3,549
Companies
19
Transactions
348
Medicare Patients
6,553
Medicare Billing
$479,836
Payment Breakdown by Category
Other$6,800 (42.1%)
Food & Beverage$5,780 (35.8%)
Travel$3,469 (21.5%)
Education$94.30 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,800 | 3 | 42.1% |
| Food and Beverage | $5,780 | 328 | 35.8% |
| Travel and Lodging | $3,469 | 15 | 21.5% |
| Education | $94.30 | 2 | 0.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $10,348 | 163 | $0 (2024) |
| Abbott Laboratories | $2,149 | 21 | $0 (2024) |
| Merck Sharp & Dohme LLC | $795.12 | 15 | $0 (2024) |
| Medtronic Vascular, Inc. | $706.56 | 6 | $0 (2018) |
| PFIZER INC. | $517.56 | 58 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $459.87 | 12 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $324.62 | 25 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $231.62 | 12 | $0 (2024) |
| Amgen Inc. | $183.62 | 12 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $107.51 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,549 | 111 | Abbott Laboratories ($1,849) |
| 2023 | $994.21 | 61 | Novartis Pharmaceuticals Corporation ($302.94) |
| 2022 | $662.06 | 59 | Novartis Pharmaceuticals Corporation ($491.32) |
| 2021 | $152.89 | 16 | Novartis Pharmaceuticals Corporation ($138.68) |
| 2020 | $434.41 | 15 | Novartis Pharmaceuticals Corporation ($161.83) |
| 2019 | $722.17 | 36 | Novartis Pharmaceuticals Corporation ($483.87) |
| 2018 | $771.03 | 22 | Merck Sharp & Dohme Corporation ($592.35) |
| 2017 | $8,857 | 28 | Novartis Pharmaceuticals Corporation ($8,152) |
All Payment Transactions
348 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $23.46 | General |
| Category: Cardiovascular | ||||||
| 12/19/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $25.30 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/19/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $2.82 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/17/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $18.75 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/16/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $23.67 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/11/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $25.04 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $17.25 | General |
| Category: Cardiovascular | ||||||
| 12/04/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $106.01 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/03/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $19.72 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/02/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $14.47 | General |
| Category: Cardiology | ||||||
| 11/27/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $22.96 | General |
| Category: DIABETES | ||||||
| 11/26/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $7.27 | General |
| Category: DIABETES | ||||||
| 11/22/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $15.02 | General |
| Category: Cardiovascular | ||||||
| 11/22/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $7.55 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 11/21/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $19.35 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $17.91 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/18/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $16.61 | General |
| Category: Cardio-renal | ||||||
| 11/15/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $13.38 | General |
| Category: Cardiology | ||||||
| 11/13/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $18.68 | General |
| Category: Cardio-renal | ||||||
| 11/08/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $19.28 | General |
| Category: Cardiovascular | ||||||
| 11/05/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $23.28 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/31/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $23.28 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/29/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $15.18 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/25/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $26.31 | General |
| Category: DIABETES | ||||||
| 10/23/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $25.34 | General |
| Category: CARDIOVASCULAR | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 22 | 1,803 | 2,199 | $474,335 | $144,049 |
| 2022 | 22 | 1,741 | 2,131 | $465,703 | $125,624 |
| 2021 | 23 | 1,859 | 2,186 | $477,209 | $140,493 |
| 2020 | 19 | 1,150 | 1,408 | $213,801 | $69,670 |
Total Patients
6,553
Total Services
7,924
Medicare Billing
$479,836
Procedure Codes
108
All Medicare Procedures & Services
108 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 406 | 652 | $180,888 | $56,660 | 31.3% |
| 93229 | Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | Office | 2023 | 42 | 43 | $82,243 | $28,829 | 35.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 102 | 102 | $43,136 | $12,711 | 29.5% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 168 | 168 | $31,669 | $8,403 | 26.5% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 110 | 112 | $27,453 | $6,922 | 25.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 31 | 33 | $12,210 | $4,384 | 35.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 40 | 69 | $12,765 | $4,265 | 33.4% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 21 | 21 | $12,878 | $3,492 | 27.1% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 266 | 278 | $12,367 | $2,656 | 21.5% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 37 | 37 | $7,526 | $2,029 | 27.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 19 | 19 | $6,593 | $1,936 | 29.4% |
| 93264 | Remote monitoring of pulmonary artery pressure sensor, up to 30 days | Office | 2023 | 11 | 47 | $6,125 | $1,880 | 30.7% |
| 93224 | Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | Office | 2023 | 25 | 25 | $5,868 | $1,370 | 23.3% |
| 93228 | Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | Office | 2023 | 64 | 66 | $4,502 | $1,303 | 28.9% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 40 | 53 | $4,198 | $1,142 | 27.2% |
| 93308 | Ultrasound of heart, follow-up | Office | 2023 | 30 | 36 | $4,295 | $964.18 | 22.4% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 12 | 15 | $2,659 | $940.71 | 35.4% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 40 | 53 | $3,921 | $892.29 | 22.8% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2023 | 41 | 45 | $2,994 | $835.92 | 27.9% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2023 | 30 | 30 | $1,724 | $468.72 | 27.2% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 52 | 57 | $1,287 | $324.87 | 25.2% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 30 | 30 | $1,150 | $316.97 | 27.6% |
| 93321 | Ultrasound of heart blood flow, valves and chambers, follow-up | Office | 2023 | 28 | 34 | $1,018 | $258.35 | 25.4% |
| 93321 | Ultrasound of heart blood flow, valves and chambers, follow-up | Facility | 2023 | 42 | 47 | $899.00 | $256.22 | 28.5% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Office | 2023 | 16 | 16 | $926.00 | $229.08 | 24.7% |
About Dr. John Everett, MD
Dr. John Everett, MD is a Cardiovascular Disease healthcare provider based in Spokane, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1336195759.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Everett, MD has received a total of $16,143 in payments from pharmaceutical and medical device companies, with $3,549 received in 2024. These payments were reported across 348 transactions from 19 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($6,800).
As a Medicare-enrolled provider, Everett has provided services to 6,553 Medicare beneficiaries, totaling 7,924 services with total Medicare billing of $479,836. Data is available for 4 years (2020–2023), covering 108 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Spokane, WA
- Active Since 05/26/2006
- Last Updated 12/01/2016
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1336195759
Products in Payments
- ENTRESTO (Drug) $9,766
- CARDIOMEMS (Device) $1,990
- HeartWare HVAD (Device) $671.47
- MK-1242 (Drug) $592.35
- LEQVIO (Drug) $515.33
- VYNDAQEL (Drug) $375.55
- XARELTO (Drug) $324.62
- JARDIANCE (Drug) $231.62
- VERQUVO (Drug) $202.77
- CardioMEMS HF System (Device) $145.47
- ELIQUIS (Drug) $142.01
- FARXIGA (Drug) $139.10
- CAMZYOS (Drug) $107.51
- Corlanor (Drug) $92.02
- Repatha (Biological) $91.60
- Kerendia (Drug) $82.99
- BRILINTA (Drug) $79.99
- EXELON PATCH (Drug) $66.19
- WATCHMAN FLX (Device) $42.95
- ONPATTRO (Drug) $38.38
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Spokane
David Bragin-Sanchez, Md, MD
Cardiovascular Disease — Payments: $223,734
Cardiovascular Disease $223,734
Dr. Michael Ring, Md, MD
Cardiovascular Disease — Payments: $174,003
Cardiovascular Disease $174,003
Joel Galloway, Md, MD
Cardiovascular Disease — Payments: $73,216
Cardiovascular Disease $73,216
Romeo Pavlic, Md, MD
Cardiovascular Disease — Payments: $44,045
Cardiovascular Disease $44,045
Ms. Deirdre Mooney, Md, Mph, MD, MPH
Cardiovascular Disease — Payments: $21,698
Cardiovascular Disease $21,698
Dr. Adam Noyes, M.d, M.D
Cardiovascular Disease — Payments: $12,670
Cardiovascular Disease $12,670